Welcome to Karessa

Karessa is a new Swedish pharmaceutical company that aims to revolutionise the market for medicinal products treating erectile dysfunction. Through innovation and patented technology, we want to help men to regain their sexual potency – without the need to plan far in advance.

Our medicinal product will not be taken in tablet form, but will instead be delivered directly into the bloodstream via a film that is applied discreetly to the oral mucosa. The main advantages for the patient include a faster and more reliable effect compared with traditional oral tablets.

Our business model is based on combining proven, effective and approved substances with our own patented drug-delivery platform. Through this combination, we are generating significant benefits, both for the patient and for Karessa itself.


Analysguiden May, 2017
Watch video (In Swedish)


Press releases

  • 2/13/2015

    Karessa's licence reinforced through patent granted in South Korea

    A recently granted patent in South Korea has reinforced Karessa's licence in the field of erectile dysfunction. This entails recognition of Karessa's technical platform as well as sole rights to the company's products on the large and growing South Korean market.

  • 2/10/2015

    Karessa's first day of trading on First North

    Today is the first trading day for Karessa (ticker code KARE) on Nasdaq Stockholm First North. Karessa is developing and commercialising the next generation of pharmaceutical products to treat erectile dysfunction. The market is worth around USD 4.3 billion and is about to undergo significant changes, opening up major opportunities for Karessa.

  • 2/6/2015

    Stefan Arver joins the Board of Karessa Pharma

    Stefan Arver, a prominent fellow, chief physician and section manager at the Karolinska University Hospital, has been appointed a new member of Karessa's Board of Directors. His recruitment further strengthens the company's expertise in the field of male sexual health.


40 per cent of all 40-year-old men are affected

40 per cent of all 40-year-old men suffer from erectile dysfunction, i.e. the inability to achieve and maintain an erection sufficient to enable successful intercourse. The reasons may be physical, mental, or a combination of both. The biggest underlying factors include age, other medications and lifestyle.

Read more about the market for medicinal products treating erectile dysfunction here.



Q1 2018


Q2 2018


Q3 2018